SGLT-2 inhibitors do not increase the risk of UTIs in diabetics

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

• Download PDF Copy

By Sally Robertson, B.Sc.Jul 31 2019Reviewed by Kate Anderton, B.Sc. (Editor)

Researchers have published reassuring findings that sodium-glucose cotransporter-2 (SGLT-2) inhibitors for the treatment of type 2 diabetes do not seem to increase the risk of urinary tract infections (UTIs) over other anti-diabetic medications.

“In a large cohort of patients seen in routine clinical practice, [the] risk for severe and non-severe UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications,” write Chintan Dave from Rutgers University and colleagues from Brigham and Women’s Hospital and Harvard Medical School.